Membrane Transport Modulators
"Membrane Transport Modulators" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that affect ION PUMPS; ION CHANNELS; ABC TRANSPORTERS; and other MEMBRANE TRANSPORT PROTEINS.
| Descriptor ID |
D049990
|
| MeSH Number(s) |
D27.505.519.562
|
| Concept/Terms |
Membrane Transport Modulators- Membrane Transport Modulators
- Modulators, Membrane Transport
- Transport Modulators, Membrane
- Membrane Transport Protein Modulators
|
Below are MeSH descriptors whose meaning is more general than "Membrane Transport Modulators".
Below are MeSH descriptors whose meaning is more specific than "Membrane Transport Modulators".
This graph shows the total number of publications written about "Membrane Transport Modulators" by people in this website by year, and whether "Membrane Transport Modulators" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 6 | 2 | 8 |
| 2018 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Membrane Transport Modulators" by people in Profiles.
-
Natural and synthetic flavonoids, novel blockers of the volume-regulated anion channels, inhibit endothelial cell proliferation. Pflugers Arch. 2018 10; 470(10):1473-1483.
-
Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2018 02; 20(2):458-462.
-
Identification of Potent Chloride Intracellular Channel Protein 1 Inhibitors from Traditional Chinese Medicine through Structure-Based Virtual Screening and Molecular Dynamics Analysis. Biomed Res Int. 2017; 2017:4751780.
-
Sodium-glucose co-transporter-2 inhibitors and diabetic ketoacidosis: An updated review of the literature. Diabetes Obes Metab. 2018 01; 20(1):25-33.
-
Antiviral activity of cationic amphiphilic drugs. Expert Rev Anti Infect Ther. 2017 05; 15(5):483-492.
-
Real-life initiation of lumacaftor/ivacaftor combination in adults with cystic fibrosis homozygous for the Phe508del CFTR mutation and severe lung disease. J Cyst Fibros. 2017 May; 16(3):388-391.
-
The effects of rhythm control strategies versus rate control strategies for atrial fibrillation and atrial flutter: a protocol for a systematic review with meta-analysis and Trial Sequential Analysis. Syst Rev. 2017 03 06; 6(1):47.
-
Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone. Diabetes Obes Metab. 2017 05; 19(5):721-728.
-
The cardiovascular benefits of empagliflozin: SGLT2-dependent and -independent effects. Diabetologia. 2017 03; 60(3):395-398.